Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
57%(4 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
1
8%
Ph phase_1
2
17%
Ph phase_4
2
17%
Ph phase_3
3
25%
Ph phase_2
4
33%

Phase Distribution

2

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
3(25.0%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

70.0%

7 of 10 finished

Non-Completion Rate

30.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(7)
Terminated(3)
Other(2)

Detailed Status

Completed7
Withdrawn2
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (16.7%)
Phase 24 (33.3%)
Phase 33 (25.0%)
Phase 42 (16.7%)
N/A1 (8.3%)

Trials by Status

withdrawn217%
terminated18%
unknown217%
completed758%

Recent Activity

0 active trials
Showing 5 of 12
terminatedphase_2

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

NCT05571267
completedphase_4

One Year Trial Evaluating Safety of Ozurdex With Eylea

NCT03984110
withdrawnphase_2

ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

NCT03374670
completedphase_3

Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema

NCT04739306
completedphase_3

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)

NCT03610646
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05571267Phase 2

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

Terminated
NCT03984110Phase 4

One Year Trial Evaluating Safety of Ozurdex With Eylea

Completed
NCT03374670Phase 2

ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Withdrawn
NCT04739306Phase 3

Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema

Completed
NCT03610646Phase 3

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)

Completed
NCT04058535Phase 1

Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD

Completed
NCT04856397Not Applicable

Ozurdex in Suboptimal Diabetic Macular Edema Patients

Unknown
NCT04572698Phase 3

A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）

Unknown
NCT03629210Phase 2

Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema

Withdrawn
NCT02591914Phase 1

An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

Completed
NCT02732899Phase 2

Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD

Completed
NCT02142296Phase 4

Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)

Completed

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12